Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): A placebo-controlled, randomised, phase 3a trial - Mosenzon, O; Blicher, T M; Rosenlund, S (Lancet Diabetes Endocrinol, 2019)
et al.